Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
36.00    0.00 (0.00%)
Bid:
35.00
Ask:
37.00
Spread: 2.00 (5.714%)
Market Cap: £16.76m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Investor Presentation

11 Mar 2021 07:00

RNS Number : 8680R
Cambridge Cognition Holdings PLC
11 March 2021
 

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Investor Presentation

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that CEO Matthew Stork and CFO Michael Holton will provide a live investor presentation on Tuesday 23 March at 6.00 p.m. London time. This follows the anticipated release of the Company's preliminary results for the year ended 31 December 2020 at 7:00 a.m. on 23 March 2021.

 

The presentation is open to all existing and potential shareholders. Those wishing to attend should email cog@investor-focus.co.uk and they will be provided with log in details. There will be the opportunity for participants to ask questions at the end of the presentation. Questions can also be emailed to the above address ahead of the presentation.

 

Enquiries:

 

Cambridge Cognition Holdings PLC

Matthew Stork, Chief Executive Officer

Michael Holton, Chief Financial Officer

Tel: 012 2381 0700

press@camcog.com

finnCap Ltd (NOMAD and Joint Broker)

Geoff Nash / Simon Hicks

Alice Lane / Charlotte Sutcliffe

Tel: 020 7220 0500

(Corporate Finance)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

Tel: 020 3903 7715

 

IFC Advisory Ltd (Financial PR and IR)

Tim Metcalfe / Graham Herring / Zach Cohen

Tel: 020 3934 6630

cog@investor-focus.co.uk

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAJMMPTMTTBBPB
Date   Source Headline
15th Dec 20149:21 amRNSDirector/PDMR Shareholding
21st Nov 20145:13 pmRNSDirector Declaration
30th Oct 20147:00 amRNSSupporting the Dementias Research Platform UK
23rd Oct 20147:00 amRNSLaunch of CTIS-Profile 2+ on Cantab Connect
1st Oct 20147:00 amRNSDirector/PDMR Shareholding
29th Sep 201412:40 pmRNSReplacement - Director/PDMR Shareholding
29th Sep 201410:06 amRNSDirector/PDMR Shareholding
24th Sep 201410:22 amRNSHolding(s) in Company
24th Sep 20147:00 amRNSDirector/PDMR Shareholding
23rd Sep 20141:29 pmRNSHolding(s) in Company
18th Sep 201411:57 amRNSIssue of Equity
11th Sep 20147:00 amRNSHalf Yearly Report
13th Aug 20147:00 amRNSExpands collaboration with Altreos
15th Jul 20147:00 amRNSNew research delivered at AAIC
3rd Jul 20144:58 pmRNSHolding(s) in Company
2nd Jul 20147:00 amRNSHalf Year Pre-Close Update
26th Jun 20147:00 amRNSHuman Abuse and Liability trial contracts won
5th Jun 20147:00 amRNS£1.6m phase III cognitive safety trial
3rd Jun 20147:00 amRNSLaunch of first two products on new platform
28th May 20147:00 amRNSCantab Mobile rolled out in NE Lincolnshire CCG
8th May 201411:03 amRNSResult of AGM
8th May 20147:00 amRNSAGM Statement
10th Apr 201411:41 amRNSPosting of Annual Report & Notice of AGM
2nd Apr 20147:00 amRNSDirectorate Change
14th Mar 20147:00 amRNSNesta report features Cambridge Cognition
13th Mar 20147:00 amRNSFinal Results
11th Mar 20147:00 amRNSProfessor Trevor Robbins wins 'The Brain Prize'
3rd Mar 20147:00 amRNSNew software launched for cognitive research
9th Jan 20147:00 amRNSAppointment of Director
16th Dec 20137:00 amRNSDavid Cameron References Cambridge Cognition
26th Nov 20137:00 amRNSCEO Review and Update
18th Sep 20137:00 amRNSHalf Yearly Report
14th Aug 20137:00 amRNSDirectorate Change
26th Jun 20137:00 amRNSProgress update on CANTABmobileT
18th Jun 20131:04 pmRNSHolding(s) in Company
19th Apr 20137:00 amRNSNHS Commissioning Board sets new DES for dementia
18th Apr 20137:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.